On Wednesday, Cameco Corporation (USA)(NYSE:CCJ)’s shares declined -3.6% to $12.30.
Cameco (CCO.TO) (CCJ) and AREVA officially marked the start of production at the Cigar Lake uranium mine and McClean Lake mill recently at the minesite in northern Saskatchewan, Canada.
Cameco president and CEO Tim Gitzel, and Olivier Wantz, member of the executive committee and senior executive vice-president, mining and front end business group for AREVA, welcomed dignitaries counting Saskatchewan Economy Minister Bill Boyd and community leaders from northern Saskatchewan, and led a tour of the underground workings.
Mining at Cigar Lake began in March 2014. The first packaged uranium concentrate was produced in October 2014 at the McClean Lake mill which is majority owned and operated by AREVA Canada Resources Inc.
Cameco Corporation produces and sells uranium worldwide. The company operates through Uranium, Fuel Services, and NUKEM segments. The Uranium segment is involved in the exploration for, mining, and milling of uranium concentrates.
Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA)’s shares dropped -1.91% to $7.18.
ARIAD Pharmaceuticals, Inc. (ARIA) declared that the first patient has been treated in its OPTIC (Optimizing Ponatinib Treatment In CML) trial of Iclusig® (ponatinib). This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is predictable to inform the optimal use of Iclusig in these patients. About 450 patients will be enrolled at clinical sites around the world.
Major Design Features of the Trial
This study will enroll patients with CP-CML who are resistant to at least two approved TKIs. These patients will be randomized equally to receive once-daily administration of 45 mg (cohort A), 30 mg (cohort B) or 15 mg (cohort C) of ponatinib. Patients in cohorts A and B will have their daily dose reduced to 15 mg upon achievement of major cytogenetic response (MCyR).
The primary endpoint of the trial is MCyR by 12 months for each cohort. Secondary endpoints comprise rate of vascular occlusive events in each dose cohort, rates of adverse events and rates of serious adverse events. Other secondary endpoints comprise cytogenetic, molecular and hematologic response rates, tolerability, duration of response, time to response, disease control rate, progression-free survival and overall survival. Preliminary data from the OPTIC trial is predictable at the end of 2016.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
At the end of Wednesday’s trade, Lowe’s Companies, Inc.(NYSE:LOW)‘s shares surged 0.12% to $68.73.
Lowe’s Companies, Inc. (LOW) declared it has agreed to sell $250 million of Floating Rate Notes due 2018, $750 million of 3.375% Notes due 2025 and $750 million of 4.375% Notes due 2045. Estimated net proceeds from this offering will be about $1.7 billion, after deducting offering expenses and underwriters’ discounts. Lowe’s intends to use the net proceeds from the sale of the Notes for the repayment of $500 million aggregate principal amount at maturity of its 5.000% Notes due October 15, 2015 and for other general corporate purposes.
Lowes Companies, Inc. operates as a home improvement retailer. The company offers products for maintenance, repair, remodeling, and home decorating. It provides home improvement products under the categories of kitchens and appliances; lumber and building materials; tools and hardware; fashion fixtures; rough plumbing and electrical; lawn and garden; seasonal living; paint; home fashions; storage and cleaning; flooring; millwork; and outdoor power equipment. The company also offers installation services through independent contractors in various product categories; extended protection plans; and in-warranty and out-of-warranty repair services. It provides national brand-name merchandise and private branded products.
Silver Wheaton Corp. (USA)(NYSE:SLW), ended its Wednesday’s trading session with -0.04% loss, and closed at $11.56.
Silver Wheaton Corp. (SLW) declares that it intends to make a normal course issuer bid (a “NCIB”) to purchase up to 20,229,671 common shares of Silver Wheaton (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”) and New York Stock Exchange (the “NYSE”).
The NCIB has been approved by the Company’s board of directors; however, it is subject to acceptance by the TSX and, if accepted, will be made in accordance with the applicable rules and policies of the TSX and the NYSE, and applicable Canadian and U.S. securities laws. Under the NCIB, Common Shares may be repurchased in open market transactions on the TSX, the NYSE, and/or other Canadian or United States exchanges, or by such other means as may be permitted by the TSX and/or the NYSE and applicable Canadian and U.S. securities laws. The price that Silver Wheaton will pay for Common Shares in open market transactions will be the market price at the time of purchase.
In accordance with TSX rules, any daily purchases (other than following a block purchase exception) on the TSX under the NCIB are limited to a maximum of 320,441 Common Shares, which represents 25% of the average daily trading volume on the TSX for the six months ended August 31, 2015. Daily purchases (other than following a block purchase exception) on the NYSE under the NCIB are limited to 25% of the average daily trading volume for the preceding four weeks. Any Common Shares that are purchased under the NCIB will be cancelled.
Silver Wheaton Corp. operates as a precious metals streaming company worldwide. The company has 18 long-term purchase agreements and 1 early deposit long-term purchase agreement associated with silver and gold regarding27 various mining assets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
